Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas

Nature Medicine volume 18, pages 1699–1704 (2012)Cite this article

Subjects

Abstract

Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin's lymphoma found in children and young adults. ALCLs frequently carry a chromosomal translocation that results in expression of the oncoprotein nucleophosmin–anaplastic lymphoma kinase (NPM-ALK). The key molecular downstream events required for NPM-ALK–triggered lymphoma growth have been only partly unveiled. Here we show that the activator protein 1 family members JUN and JUNB promote lymphoma development and tumor dissemination through transcriptional regulation of platelet-derived growth factor receptor-β (PDGFRB) in a mouse model of NPM-ALK–triggered lymphomagenesis. Therapeutic inhibition of PDGFRB markedly prolonged survival of NPM-ALK transgenic mice and increased the efficacy of an ALK-specific inhibitor in transplanted NPM-ALK tumors. Notably, inhibition of PDGFRA and PDGFRB in a patient with refractory late-stage NPM-ALK+ ALCL resulted in rapid, complete and sustained remission. Together, our data identify PDGFRB as a previously unknown JUN and JUNB target that could be a highly effective therapy for ALCL.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Effects of JUN and JUNB deletion on NPM-ALK lymphomas in mice.
Figure 2: PDGFRB is a direct transcriptional target of JUNB and JUN.
Figure 3: PDFGR inhibition interferes with formation of transplanted tumors.
Figure 4: Complete remission of ALCL in a patient after imatinib treatment.

Similar content being viewed by others

Accession codes

Accessions

Gene Expression Omnibus

References

  1. Kadin, M.E. Ki-1/CD30+ (anaplastic) large-cell lymphoma: maturation of a clinicopathologic entity with prospects of effective therapy. J. Clin. Oncol. 12, 884–887 (1994).

    Article  CAS  Google Scholar 

  2. Kadin, M.E. Primary Ki-1-positive anaplastic large-cell lymphoma: a distinct clinicopathologic entity. Ann. Oncol. 5 (suppl. 1), 25–30 (1994).

    Article  Google Scholar 

  3. Stein, H. et al. CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 96, 3681–3695 (2000).

    CAS  PubMed  Google Scholar 

  4. Morris, S.W. et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263, 1281–1284 (1994).

    Article  CAS  Google Scholar 

  5. Chen, Y. et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971–974 (2008).

    Article  CAS  Google Scholar 

  6. George, R.E. et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975–978 (2008).

    Article  CAS  Google Scholar 

  7. Janoueix-Lerosey, I. et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967–970 (2008).

    Article  CAS  Google Scholar 

  8. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non–small cell lung cancer. Nature 448, 561–566 (2007).

    Article  CAS  Google Scholar 

  9. Gambacorti-Passerini, C., Messa, C. & Pogliani, E.M. Crizotinib in anaplastic large-cell lymphoma. N. Engl. J. Med. 364, 775–776 (2011).

    Article  Google Scholar 

  10. Kwak, E.L. et al. Anaplastic lymphoma kinase inhibition in non–small cell lung cancer. N. Engl. J. Med. 363, 1693–1703 (2010).

    Article  CAS  Google Scholar 

  11. Choi, Y.L. et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N. Engl. J. Med. 363, 1734–1739 (2010).

    Article  CAS  Google Scholar 

  12. Mathas, S. et al. Aberrantly expressed c-JUN and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-κB. EMBO J. 21, 4104–4113 (2002).

    Article  CAS  Google Scholar 

  13. Staber, P.B. et al. The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood 110, 3374–3383 (2007).

    Article  CAS  Google Scholar 

  14. Chiarle, R. et al. NPM-ALK transgenic mice spontaneously develop T cell lymphomas and plasma cell tumors. Blood 101, 1919–1927 (2003).

    Article  CAS  Google Scholar 

  15. Kent, W.J. et al. The human genome browser at UCSC. Genome Res. 12, 996–1006 (2002).

    Article  CAS  Google Scholar 

  16. Cartharius, K. et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics 21, 2933–2942 (2005).

    Article  CAS  Google Scholar 

  17. The ENCODE Project Consortium. A user's guide to the encyclopedia of DNA elements (ENCODE). PLoS Biol. 9, e1001046 (2011).

  18. Andrae, J., Gallini, R. & Betsholtz, C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 22, 1276–1312 (2008).

    Article  CAS  Google Scholar 

  19. Claesson-Welsh, L. Signal transduction by the PDGF receptors. Prog. Growth Factor Res. 5, 37–54 (1994).

    Article  CAS  Google Scholar 

  20. Nissen, L.J. et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J. Clin. Invest. 117, 2766–2777 (2007).

    Article  CAS  Google Scholar 

  21. Pardanani, A. & Tefferi, A. Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders. Blood 104, 1931–1939 (2004).

    Article  CAS  Google Scholar 

  22. Ergin, M. et al. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein. Exp. Hematol. 29, 1082–1090 (2001).

    Article  CAS  Google Scholar 

  23. Gunby, R.H. et al. Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling. J. Med. Chem. 49, 5759–5768 (2006).

    Article  CAS  Google Scholar 

  24. Hantschel, O., Rix, U. & Superti-Furga, G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk. Lymphoma 49, 615–619 (2008).

    Article  CAS  Google Scholar 

  25. Stover, E.H. et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL–PDGFRB and FIP1L1–PDGFR-α in vitro and in vivo. Blood 106, 3206–3213 (2005).

    Article  CAS  Google Scholar 

  26. Qiu, L. et al. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood 108, 2407–2415 (2006).

    Article  CAS  Google Scholar 

  27. Savan, R. et al. A novel role for IL-22R1 as a driver of inflammation. Blood 117, 575–584 (2011).

    Article  CAS  Google Scholar 

  28. Pietras, K. et al. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62, 5476–5484 (2002).

    CAS  PubMed  Google Scholar 

  29. Sumida, T. et al. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model. Int. J. Cancer 128, 2050–2062 (2011).

    Article  CAS  Google Scholar 

  30. Cheng, M. et al. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol. Cancer Ther. 11, 670–679 (2012).

    Article  CAS  Google Scholar 

  31. Iqbal, J. et al. Molecular signatures to improve diagnosis in peripheral T cell lymphoma and prognostication in angioimmunoblastic T cell lymphoma. Blood 115, 1026–1036 (2010).

    Article  CAS  Google Scholar 

  32. Piccaluga, P.P. et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J. Clin. Invest. 117, 823–834 (2007).

    Article  CAS  Google Scholar 

  33. Eckerle, S. et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. Leukemia 23, 2129–2138 (2009).

    Article  CAS  Google Scholar 

  34. Piva, R. et al. Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T cell neoplasms. J. Clin. Oncol. 28, 1583–1590 (2010).

    Article  CAS  Google Scholar 

  35. Wolfer, A. et al. Inactivation of Notch1 in immature thymocytes does not perturb CD4 or CD8 T cell development. Nat. Immunol. 2, 235–241 (2001).

    Article  CAS  Google Scholar 

  36. Behrens, A. et al. Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J. 21, 1782–1790 (2002).

    Article  CAS  Google Scholar 

  37. Kenner, L. et al. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defects. J. Cell Biol. 164, 613–623 (2004).

    Article  CAS  Google Scholar 

  38. Ovcharenko, I., Nobrega, M.A., Loots, G.G. & Stubbs, L. ECR Browser: a tool for visualizing and accessing data from comparisons of multiple vertebrate genomes. Nucleic Acids Res. 32, W280–W286 (2004).

    Article  CAS  Google Scholar 

  39. Gal-Yam, E.N. et al. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc. Natl. Acad. Sci. USA 105, 12979–12984 (2008).

    Article  Google Scholar 

  40. Pflegerl, P. et al. Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. Proc. Natl. Acad. Sci. USA 106, 20423–20428 (2009).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank E.F. Wagner for providing the JUNBflox/flox and JUNflox/flox mice, A. Ostman for helpful discussions and technical help with PDGFRB analysis, and S. Reichmann for technical help with soluble-CD30 and PDGFB assays. L.K. is supported by the Fonds zur Förderung der wissenschaftlichen Forschung (FWF, P-18478-B12) and the Genome Research in Austria InflammoBiota project. R.M., V.S. and R.E. are supported by the FWF (SFB-F28) and V.S. is supported by FWF project 19723. G.E. is supported by an Elise Richter Fellowship (FWF V102-B12) and an FP7 Marie Curie International Reintegration Grant (IRG 230984). H.D. is supported by the Herzfelder Family Foundation and the Niederösterreichische Forschungs- und Bildungsges.m.b.H. P.W.V. and P.B.S. were supported by Jubiläumsfonds of the Österreichische Nationalbank (P-12147), and P.W.V. was awarded an E. Schroedinger Grant (J 2922). T.W. is supported by the Else-Kröner Fresenius Stiftung. S.P. and G.I. are supported by Italian Association for Cancer Research (AIRC) Special Program in Clinical Molecular Oncology, Milan (5x1000 No. 10007). G.I. is supported by Regione Piemonte (ONCOPROT, CIPE 25/2005); ImmOnc ('Innovative approaches to bust the immune responses', Programma Operativo Regionale, Piattaforme Innovative BIO F.E.S.R. 2007/13, Asse 1 'Ricerca e innovazione' della LR 34/2004) and the Oncology Program of Compagnia di San Paolo, Torino. R.P. is supported by AIRC grant IG-8675. R.E. is supported by the FWF Doktoratskolleg-plus Inflammation and Immunity grant, the Comprehensive Cancer Center Vienna Research Grant and the Austrian Federal Ministry of Science and Research GENAU Austromouse grant. J.M.P. is supported by the Austrian Academy of Sciences and an Advanced Grant from the European Research Council. This study was performed on behalf of the European Research Initiative on ALCL (ERIA).

Author information

Author notes

  1. Paul W Vesely, Olaf Merkel & Sabine Lagger

    Present address: Present addresses: The Scripps Research Institute, La Jolla, California (P.W.V.), National Center for Tumor Diseases, Heidelberg, Germany (O.M.) and Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh, UK (S.L.).,

  2. Daniela Laimer, Helmut Dolznig, Karoline Kollmann and Paul W Vesely: These authors contributed equally to this work.

Authors and Affiliations

  1. Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria

    Daniela Laimer, Ana-Iris Schiefer, Melanie R Hassler, Susi Heider, Lena Amenitsch, Ingrid Simonitsch-Klupp, Gerda Egger & Lukas Kenner

  2. Institute of Medical Genetics, Medical University of Vienna, Vienna, Austria

    Helmut Dolznig & Thomas Weichhart

  3. Institute of Pharmacology and Toxicology, Veterinary University Vienna, Vienna, Austria

    Karoline Kollmann & Veronika Sexl

  4. Institute of Pathology, Medical University of Graz, Graz, Austria

    Paul W Vesely & Gerald Höfler

  5. Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria

    Michaela Schlederer, Richard Moriggl & Lukas Kenner

  6. 3rd Medical Department of the Paracelsus Medical University, Laboratory for Immunological and Molecular Cancer Research, Salzburg, Austria

    Olaf Merkel

  7. Department of Internal Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria

    Melanie R Hassler & Christiane Thallinger

  8. Division of Hematology, Medical University of Graz, Graz, Austria

    Philipp B Staber

  9. Harvard Stem Cell Institute, Harvard Medical School, Boston, Massachusetts, USA

    Philipp B Staber

  10. Department of Medical Biochemistry, Max F. Perutz Laboratories, Medical University of Vienna, Vienna Biocenter, Vienna, Austria.,

    Matthias Artaker & Sabine Lagger

  11. Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK

    Suzanne D Turner

  12. Department of Hematology and Oncology 'L. and A. Seràgnoli,' S. Orsola-Malpighi Hospital, Pathology and Hematopathology Unit, University of Bologna, Bologna, Italy

    Stefano Pileri & Pier Paolo Piccaluga

  13. Department of Internal Medicine I, Division of Hematology and Hemostaseology, Comprehensive Cancer Center Drug & Target Screening Unit, Medical University of Vienna, Vienna, Austria

    Peter Valent, Medhat Shehata & Ulrich Jaeger

  14. Ludwig Boltzmann Cluster Oncology, Vienna, Austria

    Peter Valent

  15. Department of Molecular Biotechnology and Health Science, Center for Experimental Research and Medical Studies, University of Turin, Turin, Italy

    Katia Messana, Indira Landra, Maria Todaro, Roberto Piva & Giorgio Inghirami

  16. Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria

    Sylvia Knapp

  17. Department of Medicine I, Division of Infectious Diseases and Tropical Medicine, Medical University of Vienna, Vienna, Austria

    Sylvia Knapp

  18. Department of Pathology and NYU Cancer Center, New York University School of Medicine, New York, New York, USA

    Roberto Piva

  19. Department of Oncological Sciences, University of Turin, Turin, Italy

    Enzo Medico & Giorgio Inghirami

  20. Laboratory of Oncogenomics, Institute for Cancer Research and Treatment, Candiolo, Italy

    Enzo Medico

  21. Worldwide Discovery Research, Cephalon, Inc., West Chester, Pennsylvania, USA

    Bruce A Ruggeri & Mangeng Cheng

  22. Department of Internal Medicine I, Institute for Cancer Research, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria

    Robert Eferl

  23. Institute of Molecular Biotechnology of the Austrian Academy of Science, Vienna, Austria

    Josef M Penninger

Authors
  1. Daniela Laimer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Helmut Dolznig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karoline Kollmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paul W Vesely
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michaela Schlederer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Olaf Merkel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ana-Iris Schiefer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Melanie R Hassler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Susi Heider
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lena Amenitsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Christiane Thallinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Philipp B Staber
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Ingrid Simonitsch-Klupp
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Matthias Artaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Sabine Lagger
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Suzanne D Turner
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Stefano Pileri
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Pier Paolo Piccaluga
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Peter Valent
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Katia Messana
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Indira Landra
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Thomas Weichhart
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Sylvia Knapp
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Medhat Shehata
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Maria Todaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Veronika Sexl
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Gerald Höfler
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Roberto Piva
    View author publications

    You can also search for this author in PubMed Google Scholar

  29. Enzo Medico
    View author publications

    You can also search for this author in PubMed Google Scholar

  30. Bruce A Ruggeri
    View author publications

    You can also search for this author in PubMed Google Scholar

  31. Mangeng Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  32. Robert Eferl
    View author publications

    You can also search for this author in PubMed Google Scholar

  33. Gerda Egger
    View author publications

    You can also search for this author in PubMed Google Scholar

  34. Josef M Penninger
    View author publications

    You can also search for this author in PubMed Google Scholar

  35. Ulrich Jaeger
    View author publications

    You can also search for this author in PubMed Google Scholar

  36. Richard Moriggl
    View author publications

    You can also search for this author in PubMed Google Scholar

  37. Giorgio Inghirami
    View author publications

    You can also search for this author in PubMed Google Scholar

  38. Lukas Kenner
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

H.D., P.W.V., K.K., O.M., P.V., T.W., M. Shehata, V.S., G.H., G.E., J.M.P., U.J., R.M., G.I., R.E. and L.K. designed experiments. D.L., H.D., K.K., P.W.V., M. Schlederer, O.M., A.-I.S., M.R.H., S.H., L.A., C.T., P.B.S., I.S.-K., M.A., S.P., P.P.P., K.M., I.L., S.K., M. Shehata, M.T., S.L., S.D.T., R.P., E.M., G.E., R.M., M.C. and B.A.R. performed experiments and collected and analyzed data. H.D., V.S., R.M., J.M.P., G.I., R.E. and L.K. wrote the manuscript. All authors discussed the results and edited the manuscript.

Corresponding author

Correspondence to Lukas Kenner.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Case Report, Supplementary Methods, Supplementary Figs. 1–8 (PDF 1297 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Laimer, D., Dolznig, H., Kollmann, K. et al. PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas. Nat Med 18, 1699–1704 (2012). https://doi.org/10.1038/nm.2966

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm.2966

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing